January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

So, it was a healthy start to the year, M&A-wise, for one of the worst-performing sectors of the S&P 500® in 2024. The Health ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of ...

Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ:OKUR) with a Buy rating and a price target of $32.00.

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

Appoints Simon Harnest as Chief Financial Officer to advance capital markets and corporate development strategy supporting TOS-358, the Company’s lead covalent PI3Kα inhibitor, and additional ...

For PI3Kδ, p85α R649W conferred severe loss of function, as for other isoforms (Fig 3C, Fig 3 figure supplement 1C), suggesting that the absence of immunodeficiency in SHORT syndrome is not accounted ...

Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor ...

In addition, Eli Lilly has recently acquired Scorpion Therapeutics' PI3Kα inhibitor program in a deal that could reach up to $2.5 billion. Analysts from various firms such as Bernstein, BMO Capital, ...

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...